Weekly review: New FDA compliance coming, microRNAs for endometriosis, and more

Thank you for visiting the Contemporary OB/GYN website. Take a look at some of our top stories from the past week (Monday, March 23, to Friday, March 27, 2026) and click on each link to read and watch anything you may have missed.

FDA clears LiviWell's post-intercourse fluid absorption device to support vaginal health

The FDA granted clearance on March 24, 2026, to Livi, a novel device designed to support vaginal health by absorbing semen and other post-intercourse fluids. Developed by LiviWell, the product represents the introduction of a new category in intimate health care intended to address common concerns following intercourse. These include symptoms of odor and discharge, which are associated with infections like bacterial vaginosis, according to LiviWell.

Click here for more.

Alla Vash-Margita, MD, FACOG, discusses microRNAs as earlier detection biomarkers for endometriosis

Endometriosis remains a primary cause of chronic pelvic pain and infertility, yet patients face a staggering diagnostic delay of up to 14 years in adolescence. To bridge this gap, researchers at the Yale School of Medicine have identified novel biomarkers that could enable early, non-invasive detection.

Listen as Alla Vash-Margita, MD, FACOG, details how identifying differentially expressed microRNAs in 13- to 26-year-olds could provide a pathway for early detection of endometriosis.

Willow announces new breastfeeding accessories to support postpartum care

On March 24, 2026, Willow Innovations announced a national expansion of breast care and feeding accessories to assist mothers in the postpartum period, according to a news release from the company.

The 7 new breastfeeding accessories, available at Target stores and online, aim to increase the accessibility of modern maternal care products.

Click here for a detailed look at the products and when to expect availability.

FDA to issue compliance guidance for animal-derived thyroid products by August 2026

Earlier this month, the FDA announced a plan to issue new guidance for the regulation of unapproved and animal-derived thyroid medications, with intentions to issue the guidance to manufacturers by August 2026. According to a press release from the federal agency, it is actively applying a risk-based enforcement approach to unapproved, animal-derived medications.

Click here for more.

Expanded prenatal syphilis screening mandates show limited long-term impact on case detection

Researchers reported in JAMA Health Forum that while expanded prenatal syphilis mandates improve near-term detection, they require additional public health support to maintain long-term efficacy.

Click here for full findings and study details.